Lifecycle Value & Patent Thickets in Therapeutics
In the pharmaceutical domain, securing robust patent protection extends far beyond registering the primary active pharmaceutical ingredient (API). True commercial lifecycle management requires constructing overlapping layers of protection covering novel synthesis pathways, crystalline polymorphs, controlled-release delivery mechanisms, and combination therapies.
Weber Rosselli & Cannon LLP assists pharmaceutical firms and biotech research groups in navigating complex regulatory interdependencies. With deep credentials in pharmacology and organic chemistry, senior partner Thomas Rosselli rapidly digests primary clinical data to author specifications that withstand hostile generic scrutiny.
Anticipating Hatch-Waxman & PTAB Challenges
Claims drafted during early development must be positioned to withstand Paragraph IV challenges under the Hatch-Waxman Act or Inter Partes Review (IPR) petitions at the PTAB years later. Our practice excels at overcoming specialized USPTO rejections under 35 U.S.C. 103 (obviousness) and 35 U.S.C. 112 (enablement and written description) common in chemical arts.
"Life sciences IP must be positioned for the future. Claims drafted today must withstand the hostile scrutiny of Hatch-Waxman litigation or PTAB proceedings a decade from now."
Specialized Pharmaceutical Disciplines
- Small Molecule Chemistry: API Markush structures, novel intermediates, and synthetic pathways.
- Crystalline Polymorphs & Salts: X-ray powder diffraction (XRPD) claim drafting and solid-state stability protection.
- Formulation & Drug Delivery: Nanoparticle encapsulation, controlled-release matrix systems, and injectable suspensions.
- Dosage Regimens & Combinations: Synergistic drug combination claims and therapeutic dosing protocols.